A Phase 4, Multi-National, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Varenicline Compared To Placebo For Smoking Cessation Through Reduction

Trial Profile

A Phase 4, Multi-National, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Varenicline Compared To Placebo For Smoking Cessation Through Reduction

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Mar 2017

At a glance

  • Drugs Varenicline (Primary)
  • Indications Smoking withdrawal
  • Focus Therapeutic Use
  • Acronyms REDUCE TO QUIT
  • Sponsors Pfizer
  • Most Recent Events

    • 30 Mar 2017 Results of Japanese subgroup analysis (n=210) published in the British Journal of Dermatology
    • 12 Feb 2014 New trial record
    • 21 Jan 2014 Preliminary results published in a Pfizer media release (data subject to additional analyses).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top